UBS AM’s Intersect ENT, Inc XENT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-29,267
| Closed | -$820K | – | 2833 |
|
|
2022
Q1 | $820K | Buy |
29,267
+15,069
| +106% | +$413K | ﹤0.01% | 2243 |
|
|
2021
Q4 | $388K | Sell |
14,198
-11,329
| -44% | -$307K | ﹤0.01% | 2622 |
|
|
2021
Q3 | $694K | Buy |
25,527
+1,112
| +5% | +$27.5K | ﹤0.01% | 2342 |
|
|
2021
Q2 | $417K | Buy |
24,415
+10,017
| +70% | +$188K | ﹤0.01% | 2585 |
|
|
2021
Q1 | $301K | Hold |
14,398
| – | – | ﹤0.01% | 2485 |
|
|
2020
Q4 | $330K | Hold |
14,398
| – | – | ﹤0.01% | 2398 |
|
|
2020
Q3 | $235K | Hold |
14,398
| – | – | ﹤0.01% | 2365 |
|
|
2020
Q2 | $195K | Hold |
14,398
| – | – | ﹤0.01% | 2394 |
|
|
2020
Q1 | $171K | Sell |
14,398
-11,463
| -44% | -$254K | ﹤0.01% | 2319 |
|
|
2019
Q4 | $644K | Buy |
25,861
+13,761
| +114% | +$279K | ﹤0.01% | 2127 |
|
|
2019
Q3 | $206K | Sell |
12,100
-432
| -3% | -$7.86K | ﹤0.01% | 2576 |
|
|
2019
Q2 | $285K | Sell |
12,532
-7,149
| -36% | -$193K | ﹤0.01% | 2428 |
|
|
2019
Q1 | $633K | Buy |
19,681
+7,749
| +65% | +$240K | ﹤0.01% | 2012 |
|
|
2018
Q4 | $336K | Hold |
11,932
| – | – | ﹤0.01% | 2158 |
|
|
2018
Q3 | $343K | Hold |
11,932
| – | – | ﹤0.01% | 2237 |
|
|
2018
Q2 | $447K | Buy |
11,932
+4,000
| +50% | +$157K | ﹤0.01% | 2146 |
|
|
2018
Q1 | $312K | Buy |
7,932
+500
| +7% | +$18.3K | ﹤0.01% | 2193 |
|
|
2017
Q4 | $241K | Buy |
7,432
+432
| +6% | +$13K | ﹤0.01% | 2214 |
|
|
2017
Q3 | $218K | Buy |
+7,000
| New | +$207K | ﹤0.01% | 2217 |
|
|
2016
Q4 | – | Sell |
-408,717
| Closed | -$6.47M | – | 2728 |
|
|
2016
Q3 | $6.47M | Sell |
408,717
-13,651
| -3% | -$206K | 0.01% | 970 |
|
|
2016
Q2 | $5.46M | Buy |
422,368
+153,028
| +57% | +$2.4M | 0.01% | 996 |
|
|
2016
Q1 | $5.12M | Sell |
269,340
-4,451
| -2% | -$80.6K | 0.01% | 1014 |
|
|
2015
Q4 | $6.16M | Sell |
273,791
-26,155
| -9% | -$517K | 0.01% | 1000 |
|
|
2015
Q3 | $7.02M | Buy |
299,946
+29,474
| +11% | +$813K | 0.01% | 961 |
|
|
2015
Q2 | $7.74M | Buy |
+270,472
| New | +$7.09M | 0.01% | 965 |
|
UBS AM's XENT Position: Q2 2022 in Review
UBS AM sold out of Intersect ENT, Inc (XENT) in Q2 2022, closing a stake of 29,267 shares — an estimated $820K sold.
UBS AM first reported a position in XENT in Q2 2015 and held it in 25 quarters. The position peaked at $7.74M in Q2 2015. 0 funds tracked by Wall St. Rank hold XENT as of Q2 2022.
- UBS AM reported no remaining Intersect ENT, Inc position as of Q2 2022 after selling out during the quarter.
- UBS AM sold 29,267 Intersect ENT, Inc shares in Q2 2022, an estimated $820K.
- UBS AM first reported a position in Intersect ENT, Inc in Q2 2015 and held it in 25 quarters.
- UBS AM's Intersect ENT, Inc position peaked at $7.74M in Q2 2015.
- 0 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q2 2022.
Based on UBS AM's 13F filing for Q2 2022, filed 12 Aug 2022.